What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Cancer
Bob S. Carter mostly deals with Surgery, Microvesicles, Molecular biology, Prostate cancer and Aneurysm.
His research in Microvesicles intersects with topics in RNA, Biogenesis, Gene expression profiling and Cell biology.
His research on Molecular biology also deals with topics like
- Mutant that connect with fields like Gene mutation,
- Carcinogenesis which intersects with area such as Molecular genetics.
His Prostate cancer study combines topics in areas such as Prostate, Allele and Oncology.
He works mostly in the field of Allele, limiting it down to topics relating to Chromosome and, in certain cases, Tumor suppressor gene, as a part of the same area of interest.
His work carried out in the field of Aneurysm brings together such families of science as Glasgow Coma Scale, Comorbidity and Subarachnoid hemorrhage.
His most cited work include:
- Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers (3327 citations)
- Mendelian inheritance of familial prostate cancer. (663 citations)
- Family history and the risk of prostate cancer. (606 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Surgery, Cancer research, Internal medicine, Glioma and Oncology.
Surgery is closely attributed to Radiology in his study.
His Cancer research research integrates issues from microRNA and Gene.
Bob S. Carter studied Glioma and RNA that intersect with Microvesicles.
His work on Cancer expands to the thematically related Oncology.
Bob S. Carter is interested in Prostate cancer, which is a branch of Cancer.
He most often published in these fields:
- Surgery (25.73%)
- Cancer research (17.51%)
- Internal medicine (15.12%)
What were the highlights of his more recent work (between 2016-2021)?
- Cancer research (17.51%)
- Glioma (13.00%)
- Internal medicine (15.12%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Cancer research, Glioma, Internal medicine, Surgery and Glioblastoma.
His Glioma research incorporates elements of Liquid biopsy, Cancer, Flow cytometry and In vivo.
His research combines Microvesicles and Cancer.
His Flow cytometry study combines topics from a wide range of disciplines, such as microRNA and Pathology.
His Internal medicine research is multidisciplinary, incorporating perspectives in Oligodendroglioma and Oncology.
In his research, Biomarker and Extracellular vesicle is intimately related to Extracellular vesicles, which falls under the overarching field of Glioblastoma.
Between 2016 and 2021, his most popular works were:
- An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma (341 citations)
- Endonasal instrumentation and aerosolization risk in the era of COVID-19: simulation, literature review, and proposed mitigation strategies. (188 citations)
- Coding and noncoding landscape of extracellular RNA released by human glioma stem cells (185 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Surgery
His main research concerns Glioma, Extracellular vesicles, Cancer research, Glioblastoma and Molecular biology.
His Extracellular vesicles research includes elements of Angiogenesis, Gene and Extracellular vesicle.
His Molecular biology research is multidisciplinary, incorporating elements of Gene duplication, Gene rearrangement, Real-time polymerase chain reaction and Amplicon.
Cancer and Internal medicine are inherently bound to his Liquid biopsy studies.
His biological study spans a wide range of topics, including Systemic disease, Surgery, Radiation therapy and Median survival.
His studies examine the connections between Microvesicles and genetics, as well as such issues in Transfer RNA, with regards to Extracellular RNA.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
